Cannabidiol (CBD), the main nonpsychoactive constituent of Cannabis sativa, has shown a wide range of therapeutically promising pharmacological effects either as a sole drug or in combination with other drugs in adjunctive therapy. However, the targets involved in the therapeutic effects of CBD appear to be elusive. Furthermore, scarce information is available on the biological activity of its human metabolites which, when formed in pharmacologically relevant concentration, might contribute to or even account for the observed therapeutic effects. The present overview summarizes our current knowledge on the pharmacokinetics and metabolic fate of CBD in humans, reviews studies on the biological activity of CBD metabolites either in vitro or in vivo, and discusses relevant drug–drug interactions. To facilitate further research in the area, the reported syntheses of CBD metabolites are also catalogued.
Get full access to this article
View all access options for this article.
References
1.
AdamsR, HuntM, ClarkJH. Structure of cannabidiol, a product isolated from the marihuana extract of Minnesota wild hemp. I. J Am Chem Soc., 1940; 62:196–200.
2.
JacobA, ToddAR. Cannabis indica. Part II. Isolation of cannabidiol from Egyptian hashish. Observations on the structure of cannabinol. J Chem Soc., 1940; 649–653.
3.
MechoulamR, ShvoY. Hashish–I. The structure of cannabidiol. Tetrahedron., 1963; 19:2073–2078.
4.
ElSohlyM, GulW. Constituents of Cannabis sativa. In: Handbook of Cannabis (PertweeRG, ed.). Oxford University Press: Oxford, 2014, pp. 3–22.
5.
GaoniY, MechoulamR. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964; 86:1646–1647.
6.
PertweeR. (ed.). Handbook of Cannabis. Oxford University Press: Oxford, 2014.
7.
MechoulamR, HanušL. Cannabidiol: an overview of some chemical and pharmacological aspects. Part I.: chemical aspects. Chem Phys Lipids., 2002; 121:35–43.
8.
MechoulamR, PetersM, Murillo-RodriguezE, et al.Cannabidiol–recent advances. Chem Biodivers. 2007; 4:1678–1692.
9.
CascioMG, PertweeRG. Known pharmacological actions of nine nonpsychotropic phytocannabinoids. In: Handbook of Cannabis (PertweeRG, ed.). Oxford University Press: Oxford, 2014, pp. 137–156.
10.
McPartlandJM, DuncanM, Di MarzoV, et al.Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol. 2015; 172:737–753.
11.
Ibeas BihC, ChenT, NunnAVW, et al.Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015; 12:699–730.
12.
BursteinS. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015; 23:1377–1385.
13.
BergamaschiMM, Costa QueirozRH, CrippaJAS, et al.Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011; 6:237–249.
14.
ZhornitskyS, PotvinS. Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals. 2012; 5:529–552.
15.
Fernández-RuizJ, SagredoO, PazosMR, et al.Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?. Br J Clin Pharmacol. 2013; 75:323–333.
16.
MassiM, SolinasM, CinquinaV, et al.Cannabidiol as potential anticancer drug. Br J Clin Pharmacol. 2013; 75:303–312.
17.
OláhA, TóthBI, BorbíróI, et al.Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. 2014; 124:3713–3724.
DevinskyO, CilioMR, CrossH, et al.Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014; 55:791–802.
21.
WrightS, SommervilleK, JonesNA, et al.Cannabidiol. Epilepsy Res. 2015; 111:111–114.
22.
VolkowND. The biology and potential therapeutic effects of cannabidiol. Testimony before the US Senate Caucus on International Narcotics Control “Cannabidiol: barriers to research and potential medical benefits”, June242015, DHHS, NIH-NIDA, Washington, D.C. Available at: www.drugcaucus.senate.gov/sites/default/files/Volkow.pdf (accessed January31, 2016).
HarveyDJ. Metabolism and pharmacokinetics of the cannabinoids. In: Biochemistry and physiology of substance abuse (WatsonRR, ed.). CRC Press: Boca Raton, 1991, pp. 279–365.
29.
HawksworthG, McArdleK. Metabolism and pharmacokinetics of cannabinoids. In: The Medicinal Uses of Cannabis and Cannabinoids (GuyGW, WhittleBA, RobsonPJ, eds.). Pharmaceutical Press: London, 2004, pp. 205–228.
30.
HuestisMA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007; 4:1770–1804.
31.
HuestisMA, SmithML. Cannabinoid pharmacokinetics and disposition in alternative matrices. In: Handbook of Cannabis (PertweeRG, ed.). Oxford University Press: Oxford, 2014, pp. 296–316.
32.
UjváryI, GrotenhermenF. 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol—a ubiquitous yet underresearched cannabinoid. A review of the literature. Cannabinoids., 2014; 9:1–8. Available at: www.cannabis-med.org/data/pdf/en_2014_01_1.pdf (accessed January31, 2016).
33.
OhlssonA, LindgrenJ-E, AnderssonS, et al.Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intraveous administration. Biomed Environ Mass Spectrom. 1986; 13:77–83.
34.
WallME, BrineDR, Perez-ReyesM. Metabolism of cannabinoids in man. In: The Pharmacology of Marihuana (BraudeMC, SzaraS, eds.). Raven Press: New York, 1976, pp. 93–113.
35.
AgurellS, CarlssonS, LindgrenJE, et al.Interactions of Δ1-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia., 1981; 37:1090–1092.
36.
NadulskiT, PragstF, WeinbergG, et al.Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Δ9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Ther Drug Monit. 2005; 27:799–810.
37.
EichlerM, SpinediL, Unfer-GrauwilerS, et al.Heat exposure of Cannabis sativa extracts affects the pharmacokinetic and metabolic profile in healthy male subjects. Planta Med. 2012; 78:686–691.
38.
ConsroeP, KennedyK, SchramK. Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav. 1991; 40:517–522.
39.
ConsroeP, LagunaJ, AllenderJ, et al.Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav. 1991; 40:701–708.
40.
Fusar-PoliP, CrippaJA, BhattacharyyaS, et al.Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009; 66:95–105.
41.
ManiniAF, YiannoulosG, BergamaschiMM, et al.Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med. 2015; 9:204–210.
42.
GuyGW, FlintME. A single centre, placebo-controlled, four period, crossover, tolerability study assessing, pharmacodynamic effects, pharmacokinetic characteristics and cognitive profiles of a single dose of three formulations of Cannabis Based Medicine Extracts (CBMEs) (GWPD9901) plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a Cannabis Based Medicine Extract given via two administration routes (GWPD9901 Ext). J Cannabis Ther. 2003; 3:35–77.
43.
KarschnerEL, DarwinWD, GoodwinRS, et al.Plasma cannabinoid pharmacokinetics following controlled oral Δ9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin Chem. 2011; 57:66–75.
44.
StottCG, WhiteL, WrightS, et al.A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray. Eur J Clin Pharmacol. 2013; 69:1135–1147.
45.
StinchcombAL, ValivetiS, HammellDC, et al.Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol. 2004; 56:291–297.
46.
LodzkiM, GodinB, RakouL, et al.Cannabidiol–transdermal delivery and anti-inflammatory effect in a murine model. J Control Release. 2003; 93:377–387.
47.
PaudelKS, HammellDC, AguRU, et al.Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. 2010; 36:1088–1097.
48.
MattesRD, EngelmanK, ShawLM, et al.Cannabinoids and appetite stimulation. Pharmacol Biochem Behav. 1994; 49:187–189.
49.
BrenneisenR, EgliA, ElSohlyMA, et al.The effect of orally and rectally administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther. 1996; 34:446–452.
50.
GronewoldA, SkoppG. A preliminary investigation on the distribution of cannabinoids in man. Forensic Sci Int. 2011; 210:e7–e11.
51.
FabritiusM, StaubC, ManginP, et al.Distribution of free and conjugated cannabinoids in human bile samples. Forensic Sci Int. 2012; 223:114–118.
52.
SiemensAJ, WalczakD, BuckleyFE. Characterization of blood disappearance and tissue distribution of [3H]cannabidiol. Biochem Pharmacol. 1980; 29:462–464.
53.
AlozieSO, MartinBR, HarrisLS, et al.3H-Δ9-Tetrahydrocannabinol, 3H-cannabinol and 3H-cannabidiol: penetration and regional distribution on rat brain. Pharmacol Biochem Behav. 1980; 12:217–221.
54.
DeianaS, WatanabeA, YamasakiY, et al.Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarin (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive beaviour. Psychopharmacology. 2012; 219:859–873.
55.
BugginsTR, DickinsonPA, TaylorG. The effects of pharmaceutical excipients on drug disposition. Adv Drug Deliv Rev. 2007; 59:1482–1503.
56.
EngelA, OswaldS, SiegmundW, et al.Pharmaceutical excipients influence the function of human uptake transporting proteins. Mol Pharm. 2012; 9:2577–2581.
57.
KarlerR, SangdeeP, TurkanisSA, et al.The pharmacokinetic fate of cannabidiol and its relationship to barbiturate sleep time. Biochem Pharmacol. 1979; 28:777–784.
58.
ChristiansenJ, RafaelsenOJ. Cannabis metabolites in urine after oral administration. Psychopharmacologia. 1969; 15:60–63.
59.
NilssonI, AgurellS, NilssonJLG, et al.Two cannabidiol metabolites formed by rat liver. J Pharm Pharmacol. 1973; 25:486–487.
60.
NilssonIM, AgurellS, LeanderK, et al.Cannabidiol: structure of three metabolites formed in rat liver. Acta Pharm Suec. 1971; 8:70–1.
61.
HarveyDJ, SamaraE, MechoulamR. Urinary metabolites of cannabidiol in dog, rat and man and their identification by gas chromatography–mass spectrometry. J Chromatogr. 1991; 562:299–322.
62.
HarveyDJ, MechoulamR. Metabolites of cannabidiol identified in human urine. Xenobiotica. 1990; 20:303–320.
63.
JiangR, YamaoriS, TakedaS, et al.Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci. 2011; 89:165–170.
64.
DüsingRH. Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (Δ2(E)-valproate) in healthy male volunteers. Pharm Weekbl Sci. 1992; 14:152–158.
65.
MazurA, LichtiCF, PratherPL, et al.Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos. 2009; 37:1496–1504.
66.
BergamaschiMM, BarnesA, QueirozRHC, et al.Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine. Anal Bioanal Chem. 2013; 405:4679–4689.
67.
Sachse-SeebothC, PfeilJ, SehrtD, et al.Interindividual variation in the pharmacokinetics of Δ9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Clin Pharmacol Ther. 2009; 85:273–276.
68.
ShaniA, MechoulamR. Photochemical reactions of cannabidiol. Cyclization to Δ1-tetrahydrocannabinol and other transformations. Tetrahedron., 1971; 27:601–606.
69.
YamamotoI, GohdaH, NarimatsuS, et al.Identification of cannabielsoin, a new metabolite of cannabidiol formed by guinea-pig hepatic microsomal enzymes, and its pharmacological activity in mice. J Pharmacobiodyn. 1988; 11:833–838.
70.
YamamotoI, GohdaH, NarimatsuS, et al.Cannabielsoin as a new metabolite of cannabidiol in mammals. Pharmacol Biochem Behav. 1991; 40:541–546.
71.
MechoulamR, Ben-ZviZ, GaoniY. Hashish–XIII: on the nature of the Beam test. Tetrahedron. 1968; 24:5615–5624.
72.
HajCG, SumariwallaPF, HanušL, et al.HU-444, a novel, potent anti-inflammatory, nonpsychotropic cannabinoid. J Pharmacol Exp Ther. 2015; 355:66–75.
73.
KozelaE, HajC, HanušL, et al.HU-446 and HU-465, derivatives of the non-psychoactive cannabinoid cannabidiol, decrease the activation of encephalitogenic T cells. Chem Biol Drug Des. 2016; 87:143–153.
74.
NyeJS, SeltzmanHH, PittCG, et al.High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium Δ8-tetrahydrocannabinol. J Pharmacol Exp Ther. 1985; 234:784–791.
75.
BisognoT, HanušL, de PetrocellisL, et al.Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol. 2001; 134:845–852.
76.
FrideE, FeiginC, PondeDE, et al.(+)-Cannabidiol analogues which bind cannabinoid receptors but exert peripheral activity only. Eur J Pharmacol. 2004; 506:179–188.
77.
HanušLO, TchilibonS, PondeDE, et al.Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. Org Biomol Chem. 2005; 3:1116–1123.
78.
BornheimLM, EverhartET, LiJ, et al.Characterization of cannabidiol-mediated cytochrome P450 inactivation. Biochem Pharmacol. 1993; 45:1323–1331.
79.
JiangR, YamaoriS, OkamotoY, et al.Cannabidiol is a potent inhibitor of the catalytic acitivity of cytochrome P450 2C19. Drug Metab Pharmacokinet. 2013; 28:332–338.
80.
MechoulamR, TchilibonS, FrideE, et al.Pharmaceutical compositions comprising cannabidiol derivatives. US Patent 7759526, 2010.
81.
WatanabeK, UsamiN, YamamotoI. Inhibitory effect of cannabidiol hydroxy-quinone, an oxidative product of cannabidiol, on the hepatic microsomal drug-metabolizing enzymes of mice. J Pharmacobiodyn. 1991; 14:421–427.
82.
BornheimLM, GrilloMP. Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator. Chem Res Toxicol. 1998; 11:1209–1216.
83.
WuH-Y, HanT-R. Cannabidiol hydroxyquinone-induced apoptosis of splenocytes is mediated predominantly by thiol depletion. Toxicol Lett. 2010; 195:68–74.
84.
KoganNM, SchlesingerM, PrielE, et al.HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther. 2007; 6:173–183.
85.
RegalKM, MercerSL, DeweeseJE. HU-331 is a catalytic inhibitor of topoisomerase IIα. Chem Res Toxicol. 2014; 27:2044–2051.
86.
PetersM, KoganNM. HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. Expert Opin Investig Drugs. 2007; 16:1405–1413.
87.
FrideE, PondeD, BreuerA, et al.Peripheral, but not central effects of cannabidiol derivatives: mediation by CB1 and unidentifed receptors. Neuropsychopharmacology. 2005; 48:1117–1129.
88.
GreenK, SymondsCM, OliverNW, et al.Intraocular pressure following systemic administration of cannabinoids. Curr Eye Res. 1982–1983;2:247–253.
89.
UlissDB, RazdanRK, DaizellHC. Stereospecific intramolecular epoxide cleavage by phenolate anion. Synthesis of novel and biologically active cannabinoids. J Am Chem Soc., 1974; 96:7372–7374.
90.
ElSohlyMA, HarlandEC, BenigniDA, et al.Cannabinoids in glaucoma II: the effect of different cannabinoids in intraocular pressure of the rabbit. Curr Eye Res. 1984; 3:841–850.
91.
CarliniEA, MechoulamR, LanderN. Anticonvulsant activity of four oxygenated cannabidiol derivatives. Res Commun Chem Pathol Pharmacol. 1975; 12:1–15.
92.
SamaraE, BialerM, HarveyDJ. Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog. Xenobiotica. 1990; 20:177–183.
93.
PertweeRG. The pharmacology and therapeutic potential of cannabidiol. In: Cannabinoids (Di MarzoV, ed.). Landes Bioscience: Georgetown, TX, 2004, pp. 32–83.
94.
AdamsR. Marijuana. Bull N Y Acad Med. 1942; 18:705–730.
95.
PatonWDM, PertweeRG. Effect of cannabis and certain of its constituents on pentobarbital sleeping time and phenazone metabolism. Br J Pharmacol. 1972; 44:250–261.
96.
DaltonWS, MartzR, RoddaBE, et al.Influence of cannabidiol on secobarbital effects and plasma kinetics. Clin Pharmacol Ther. 1976; 20:695–700.
97.
BenowitzNL, NguyenT-L, JonesRT, et al.Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther. 1980; 28:115–120.
98.
StoutSM, CiminoNM. Exogenous cannabinoids as substrates, inhibitors and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014; 46:86–95.
99.
BornheimLM, EverhartET, LiJ, et al.Induction and genetic regulation of mouse hepatic cytochrome P450 by cannabidiol. Biochem Pharmacol. 1994; 48:161–171.
100.
YamaoriS, KinugasaY, JiangR, et al.Cannabidiol induces expression of human cytochrome P450 1A1 that is possibly mediated through aryl hydrocarbon receptor signaling in HepG2 cells. Life Sci. 2015; 136:87–93.
101.
BornheimLM, KimKY, ChenB, et al.The effect of cannabidiol on mouse hepatic microsomal cytochrome P450-dependent anandamide metabolism. Biochem Biophys Res Commun. 1993; 197:740–746.
102.
StottC, WhiteL, WrightS, et al.A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers. Springerplus. 2013; 2:23–6.
103.
GeffreyAL, PollackSF, BrunoPL, et al.Drug–drug interaction between clobazepam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015; 56:1246–1251.
104.
ZhuH-J, WangJ-S, MarkowitzJS, et al.Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther. 2006; 317:850–857.
105.
HollandML, AllenJD, ArnoldJC. Interaction of plant cannabinoids with the multidrug transporter ABCC1(MRP1). Eur J Pharmacol. 2008; 591:128–131.
106.
ArnoldJC, HoneP, HollandML, et al.CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. Pharmacol Rep. 2012; 64:751–757.
107.
FeinshteinV, ErezO, Ben-ZviZ, et al.Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ. 2013; 1:e15–3.
108.
HarveyDJ. Mass spectrometry of the cannabinoids and their metabolites. Mass Spectrom Rev. 2013; 6:135–229.
109.
AgurellS, DahménJ, GustafssonB, et al.Metabolic fate of tetrahydrocannabinol. In: Cannabis and its derivatives: pharmacology and experimental psychology (PatonWDM, CrownJ, eds.). Oxford University Press: London, 1972, pp. 16–38.
110.
BinderM, AgurellS, LeanderK, et al.Zur Identifikation potentieller Metabolite von Cannabis-Inhaltstoffen: Kernresonanz- und massen-spektroskopische Untersuchungen an seitenkettenhydroxylierte Cannabinoiden. Helv Chim Acta. 1974; 57:1626–1641.
111.
LanderN, Ben-ZviZ, MechoulamR, et al.Total syntheses of cannabidiol and Δ1-tetrahydrocannabinol metabolites. J Chem Soc Perkin, 1. 1976;(1):8–16.
112.
KobayashiY, TakeuchiA, WangY-G. Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate. Org Lett. 2006; 8:2699–2702.
113.
TchilibonS, MechoulamR. Synthesis of a primary metabolite of cannabidiol. Org Lett. 2000; 2:3301–3303.
114.
JorapurVS, DuffleyRP, RazdanRK. A procedure for the conversion of cannabidiol into 12β-substituted tetrahydrocannabinols (THC's): synthesis of 12β-hydroxy-Δ8-THC. Synth Commun. 1984; 14:655–660.
115.
YamamotoI, GohdaH, NarimatsuS, et al.Mechanism of biological formation of cannabielsoin from cannabidiol in the guinea-pig, mouse, rat and rabbit. J Pharmacobiodyn. 1989; 12:488–494.
116.
YamamotoI, NagaiK, WatanabeK, et al.A novel metabolite, an oxepin formed from cannabidiol with guinea-pig hepatic microsomes. J Pharm Pharmacol. 1995; 47:683–686.
117.
RobertsonLW, KohS-W, HuffSR, et al.Microbiological oxidation of the pentyl side chain of cannabinoids. Experientia. 1978; 34:1020–1022.
118.
MechoulamR, FrideE. Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives. US Patent 7884133, 2011.
119.
MartinBR, HarveyDJ, PatonWDM. Biotransformation of cannabidiol in mice: identification of new acid metabolites. Drug Metab Dispos. 1977; 5:259–267.
120.
HarveyDJ, MartinBR, PatonWDM. Comparative in vivo metabolism of Δ1-tetrahydrocannabinol (Δ1-THC), cannabidiol (CBD) and cannabinol (CBN) by several species. In: Recent developments in mass spectrometry in biochemistry and medicine, Vol. 2 (FrigerioA, ed.). Plenum Press: New York, 1978, pp. 161–184.
121.
HarveyDJ, BrownNK. In vitro metabolism of cannabidiol in the rabbit: identification of seventeen new metabolites including thirteen dihydroxylated in the isopropenyl side chain. Biomed Environ Mass Spectrom. 1990; 19:559–567.
122.
SamaraE, BialerM, HarveyDJ. Identification of urinary metabolites of cannabidiol in the dog. Drug Metab Dispos. 1978; 18:571–579.
123.
CrombieL, CrombieWML, TuchindaP. Synthesis of cannabinoids carrying ω-carboxy substituents: the cannabidiols, cannabinol and Δ1- and Δ6-tetrahydrocannabinols of this series. J Chem Soc Perkin 1. 1988; 1255–1262.
124.
MakriyannisA, NikasSP, AlapafujaSO. Angiogenic resorcinol derivatives. WO 2011/006099, 2011.
125.
LyleMA, PallanteS, HeadK, et al.Synthesis and characterization of glucuronides of cannabinol, cannabidiol, Δ9-tetrahydrocannabinol and Δ8-tetrahydrocannabinol. Biomed Mass Spectrom. 1977; 4:190–196.
126.
KüppersFJEM, LousbergRJJC, BerchtCAL, et al.Cannabis-VIII. Pyrolysis of cannabidiol. Structure elucidation of the main pyrolytic product. Tetrahedron., 1973; 29:2797–2802.
127.
ShaniA, MechoulamR. Cannabielsoic acids. Isolation and synthesis by a novel oxidative cyclization. Tetrahedron., 1974; 30:2437–2446.
128.
HartselSC, LohWH-T, RobertsonLW. Biotransformation of cannabidiol to cannabielsoin by suspension cultures of Cannabis sativa and Saccharum officinarum. Planta Med. 1983; 48:17–19.
129.
ObachRS. Pharmacologically active drug metabolites: impact on drug discovery and pharmacotherapy. Pharmacol Rev. 2013; 65:578–640.
130.
ZuardiAW, HallakJEC, DursunSM, et al.Cannabidiol monotherapy for treatment-resistance schizophrenia. J Psychopharmacol. 2006; 20:683–686.
131.
WatanabeK, ItokawaY, YamaoriS, et al.Conversion of cannabidiol to Δ9-tetrahydrocannabinol and related cannabinoids in artifical gastric juice, and their pharmacological effects in mice. Forensic Toxicol. 2007; 25:16–21.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
